3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
4
Neoplasm Metastasis
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Ovarian Neoplasms
2
Neoplasms
2
Leukemia, Myeloid, Chronic-Phase
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Brain Neoplasms
2
Vaping
1
Urinary Bladder Neoplasms
1
Tobacco Use Disorder
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligodendroglioma
1
Neoplasms by Histologic Type
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hematologic Diseases
1
Interventions
Imatinib Mesylate
5
ruxolitinib
4
ponatinib
4
nilotinib
4
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
4
Azacitidine
3
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Cyclophosphamide
2
Busulfan
2
spartalizumab
1
sonidegib
1
simtuzumab
1
sabatolimab
1
pembrolizumab
1
ibrutinib
1
bosutinib
1
Zoledronic Acid
1
Sertraline
1
SCIO-469
1
Quality of Life
1
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
Lenalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bone Marrow Diseases
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts